Viatris Inc. (VTRS)

NASDAQ: VTRS · Real-Time Price · USD
8.71
+0.02 (0.23%)
At close: Jun 3, 2025, 4:00 PM
8.82
+0.11 (1.26%)
After-hours: Jun 3, 2025, 6:21 PM EDT
0.23%
Market Cap 10.22B
Revenue (ttm) 14.33B
Net Income (ttm) -3.79B
Shares Out 1.17B
EPS (ttm) -3.18
PE Ratio n/a
Forward PE 3.85
Dividend $0.48 (5.51%)
Ex-Dividend Date May 23, 2025
Volume 20,433,713
Open 8.60
Previous Close 8.69
Day's Range 8.40 - 8.84
52-Week Range 6.85 - 13.55
Beta 0.89
Analysts Hold
Price Target 10.50 (+20.55%)
Earnings Date May 8, 2025

About VTRS

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CN... [Read more]

Sector Healthcare
Founded 1961
Employees 32,000
Stock Exchange NASDAQ
Ticker Symbol VTRS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for VTRS stock is "Hold." The 12-month stock price forecast is $10.5, which is an increase of 20.55% from the latest price.

Price Target
$10.5
(20.55% upside)
Analyst Consensus: Hold
Stock Forecasts

News

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Viatris To Contact Him Directly To Discuss Their Options

1 day ago - GlobeNewsWire

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

MR-142 Achieved Primary Endpoint of ≥15-letter (≥3-line) Gain in Mesopic Low Contrast Distance Visual Acuity in Comparison to Placebo Results Showed Patient-Reported Functional Benefit in Treating Sig...

1 day ago - PRNewsWire

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Viatris To Contact Him Directly To Discuss Their Options If you purchased or acquired...

3 days ago - PRNewsWire

VTRS CLASS NOTICE: Viatris Inc. Investors may have been Affected by Fraud – Contact BFA Law before June 3 Court Deadline (NASDAQ:VTRS)

NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company...

3 days ago - GlobeNewsWire

SHAREHOLDER REMINDER: Berger Montague Reminds Viatris (NASDAQ: VTRS) Investors of the June 3, 2025 Deadline

PHILADELPHIA, May 30, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTR...

4 days ago - GlobeNewsWire

DEADLINE NEXT WEEK: Berger Montague Advises Viatris (NASDAQ: VTRS) Investors to Contact the Firm Before June 3, 2025

PHILADELPHIA, May 27, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTR...

7 days ago - GlobeNewsWire

VTRS FRAUD: Suffer Losses on Viatris Inc.? You may have been Affected by Fraud and are Urged to Contact BFA Law (NASDAQ:VTRS)

NEW YORK, May 25, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company...

9 days ago - GlobeNewsWire

VTRS FRAUD NEWS: Viatris Inc. is Being Sued for Securities Fraud; Investors That Lost Money Are Urged to Contact BFA Law by June 3 Court Deadline

NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ:VTRS) and certain of th...

11 days ago - Accesswire

Viatris to Participate in Upcoming Investor Conferences

PITTSBURGH , May 22, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in June 202...

12 days ago - PRNewsWire

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Viatris Lawsuit – VTRS

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).

13 days ago - GlobeNewsWire

VTRS LAWSUIT: Lose Money on Viatris Inc.? Contact BFA Law before June 3 Court Deadline

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company...

13 days ago - GlobeNewsWire

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options

20 days ago - GlobeNewsWire

Viatris Inc. (VTRS) BofA Securities 2025 Healthcare Conference (Transcript)

Viatris Inc. (NASDAQ:VTRS) BofA Securities 2025 Healthcare Conference May 13, 2025 8:00 PM ET Company Participants Doretta Mistras - CFO Philippe Martin - Chief R&D Officer Conference Call Participan...

20 days ago - Seeking Alpha

Viatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock Soars

Viatris Inc. VTRS on Thursday, released data from Phase 3 study evaluating the contraceptive efficacy and safety of XULANE LO low dose weekly dermal patch of 150 mcg norelgestromin and 17.5 mcg ethiny...

26 days ago - Benzinga

Viatris Q1 Earnings Review: Shares Are Up, Time To Sell (Rating Downgrade)

Viatris Inc.'s Q1 2025 earnings show declining revenues and profits, yet the stock rose nearly 10% due to stable full-year guidance and positive pipeline updates. The company's significant debt reduct...

26 days ago - Seeking Alpha

Viatris Inc. (VTRS) Q1 2025 Earnings Call Transcript

Viatris Inc. (NASDAQ:VTRS) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer...

26 days ago - Seeking Alpha

Viagra-maker Viatris beats quarterly estimates on demand for branded drugs in China

Drugmaker Viatris beat Wall Street estimates for first-quarter profit and revenue on Thursday, helped by sales of its branded drugs in China.

26 days ago - Reuters

Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook

Delivers Total Revenues in Line With Expectations Demonstrating Strength of the Base Business Makes Significant Pipeline Progress With Three Positive Phase 3 Data Readouts  Returns More Than $450 Mill...

26 days ago - PRNewsWire

Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential

Treatment With XULANE LO Low Estrogen Dose Achieved Primary and All Secondary Efficacy and Safety Endpoints Results Demonstrated Potential Best-In-Class Patch Performance  New Drug Application Submiss...

26 days ago - PRNewsWire

Viatris' pain drug meets main goals of two late-stage trials

Viatris said on Thursday that its fast-acting form of generic pain drug meloxicam met the main goals of two late-stage studies.

26 days ago - Reuters

Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain

All Primary and Secondary Endpoints Were Met in Both Phase 3 Studies In Both Acute Pain Models, MR-107A-02 Demonstrated Statistically Significant and Clinically Meaningful Improvement in Pain Compared...

26 days ago - PRNewsWire

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Viatris Inc. Lawsuit - VTRS

NEW YORK , May 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS). Shareholders who purchased shares of VTRS during the class period ...

26 days ago - PRNewsWire

VTRS SECURITIES UPDATE: Viatris Inc. Investors with Losses may have been affected by Fraud – Contact BFA Law by June 3 Court Deadline (NASDAQ:VTRS)

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company...

27 days ago - GlobeNewsWire

Viatris Announces Quarterly Dividend

PITTSBURGH , May 7, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on May 5, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and ou...

27 days ago - PRNewsWire